Bhargava Kandala

Bhargava Kandala

Central US Merck & Co., Inc. - Kenilworth / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 5388016
-
person_outline Bhargava Kandala's MOST POPULAR ARTICLES
1-) Clinical evaluation of MK‐2640: An insulin analog with glucose‐responsive propertiesAW Krug, SAG Visser, K Tsai, B Kandala, C Fancourt, B Thornton, ...Clinical Pharmacology & Therapeutics 105 (2), 417-425, 2019332019
2-) Can pharmacokinetic studies assess the pulmonary fate of dry powder inhaler formulations of fluticasone propionate?G Hochhaus, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, SK Drescher, ...The AAPS journal 23, 1-14, 2021172021
3-) CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialAJ Armstrong, R Geva, HC Chung, C Lemech, WH Miller Jr, AR Hansen, ...Investigational New Drugs 42 (1), 145-159, 2024162024
4-) A Model‐Informed Drug Discovery and Development Strategy for the Novel Glucose‐Responsive Insulin MK‐2640 Enabled Rapid Decision MakingSAG Visser, B Kandala, C Fancourt, AW Krug, CR ChoClinical Pharmacology & Therapeutics 107 (6), 1296-1311, 2020122020
5-) Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approachB Kandala, N Plock, A Chawla, A Largajolli, S Robey, K Watson, ...EBioMedicine 84, 2022102022